Biosergen discusses positive results in patients with deadly fungal infections
So far, the majority of patients involved in Biosergen’s proof-of-concept study for life-threatening fungal infections have been able to leave the hospital. This suggests the potential effect of BSG005 even at low doses. Moreover, the subscription period for the company’s TO3 warrants is approaching, which will take place between November 18 and 29. Listen to Tine Olesen, CEO, talk more about this.
Watch the interview with CEO Tine Olesen below:
